Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan Seeks To Extend Botox Use To Overactive Bladder

This article was originally published in The Pink Sheet Daily

Executive Summary

During an R&D day March 28, Allergan highlighted its growth strategy for Botox, which includes expansion into new indications like overactive bladder; the company submitted an sBLA for the indication.

You may also be interested in...

Astellas Expands Its Presence In Urology With Myrbetriq Approval

Astellas is tasked with introducing a new product into the already crowded overactive bladder market now that it has gained approval for the beta-3 antagonist mirabegron in the U.S.

A Headache For Map: Levadex Gets “Complete Response” Letter From FDA

The agency raised issues related to the chemistry, manufacturing and controls section of the dihydroergotamine NDA, as well as concerns stemming from inspection of a third-party manufacturing facility, the company says.

Allergan And MAP Team Up On Inhalable Migraine Treatment

Deal with Allergan focuses on detailing to neurologists and pain specialists, leaving MAP free to do other co-promotion deals.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts